Advanced Search:
Equity Index Forex Crypto Commodity

ABBV - AbbVie

$162.28  -3.69 (-2.22%)

Updated: 03:14 May 5, 2024 EST

Next Hour's AI Forecast

98.92%

Avg. Accuracy (AI)

$157.89

Next Session's AI Forecast

98.02%

Avg. Accuracy (AI)

$164.26

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

$159.17

AbbVie's Position Within the Drug Manufacturers—General Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

ABBVIE - HISTORICAL DATA 6M

  • Last price

    $ 162.28

  • Daily change

    $ -3.69

  • Previous Close

    $ 165.97

  • Last Updated

    03:14 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.21 -0.22 -0.13 0.12 0.04

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.02 1.09 0.94 0.85 0.85

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
64.43% 40.55% 29.56% 13.83%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
162.64 -0.94% 164.18 -3.01% 169.27 4.62% 161.8

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.2 66.67 0.87 16.67

AbbVie Technical Analysis News

AbbVie

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com

Sectors: Healthcare
Industry: Drug Manufacturers—General
F. Time Employees: 50000
Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Corporate Governance

AbbVie Inc.’s ISS Governance QualityScore as of May 1, 2024 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 9; Compensation: 3.

ABBVIE'S HOLDERS RANK

List of holders with stock participation in AbbVie.

Holder Rank Holder Shares Date Reported % Out Value